Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Roche joining forces to forward precision oncology

Published: 11 Dec 2017

Views: 2205

Rating:

Save

Ian Walker - Roche Foundation Medicine, Basel, Switzerland

Ian Walker talks to ecancer at EAPM 2017 in Belfast.

He spoke about precision oncology and how joining forces with other pharmaceutical companies will greatly aid patients in Europe.

This is important because metastatic cancers are so diverse, so a lot of data is needed.

Related Videos

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus

Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale...

ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus ( Dr Anna Minchom, Prof Enriqueta Felip, Prof Nicolas Girard and Prof Pascale Tomasini )

Choosing Wisely in pathology

Dr Angela Mlole - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely in pathology ( Dr Angela Mlole - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

Choosing Wisely in radiology Tanzania

Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania

Choosing Wisely in radiology Tanzania ( Dr Revelian Iramu - Ocean Road Cancer Institute, Dar es Salaam, Tanzania )

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant...

Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA

Combination of camonsertib plus PARPi shows clinical activity in DDR-aberrant tumours ( Dr Timothy Yap - The University of Texas MD Anderson Cancer Center, Houston, USA )

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+...

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )

The placebo effect in oncology trials and the criteria for approving drugs

Dr Bishal Gyawali - Queen's University, Kingston, Canada

The placebo effect in oncology trials and the criteria for approving drugs ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )

Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally...

Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium

Pembrolizumab with chemoradiation therapy vs placebo plus CRT for locally advanced head and neck squamous cell carcinoma ( Prof Jean-Pascal Machiels - Cliniques Universitaires Sain-Luc, Brussels, Belgium )

CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper...

Dr Cristina Suarez - Vall d’Hebron University Hospital, Catalonia, Spain

CheckMate 9ER: aRCC patients on nivolumab plus cabozantinib achieved deeper responses vs sunitinib ( Dr Cristina Suarez - Vall d’Hebron University Hospital, Catalonia, Spain )

Ibrutinib improves PFS by 50% for older patients with newly diagnosed mantle...

Dr Michael Wang - MD Anderson Cancer Center, Houston, USA

Ibrutinib improves PFS by 50% for older patients with newly diagnosed mantle cell lymphoma ( Dr Michael Wang - MD Anderson Cancer Center, Houston, USA )

More from ecancer